Sign inJoin waitlistJoin the waitlist

Anjay Rastogi

Clinical Chief of Nephrology · UCLA David Geffen School of Medicine/UCLA Medical Center

Credentials: · · · · ·

History

Nephrology Division · UCLA David Geffen School of Medicine/UCLA Medical Center
Present
UCLA David Geffen School of Medicine/UCLA Medical Center
Present
UCLA David Geffen School of Medicine/UCLA Medical Center
Present

Nephrology
UCLA David Geffen School of Medicine/UCLA Medical Center
2003–2005
Department of Molecular and Medical Pharmacology David Geffen School of Medicine, UCLA
2004
Internal Medicine
UCLA David Geffen School of Medicine/UCLA Medical Center
1998–2001
SAWAI MAN SINGH MED COLL, RAJASTHAN UNIV, JAIPUR, RAJASTHAN
1989–1993

Research

American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis
Arthritis Care & Research · 2012 · 1,053 citations
In-center hemodialysis six times per week versus three times per week
New England Journal of Medicine · 2010 · 796 citations
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan
Review · Journal of the American Society of Nephrology · 2018 · 210 citations

Farid Arman
15 papers · 3 as a resident
Niloofar Nobakht
14 papers · 1 as a fellow
Ramy Hanna
14 papers
Mohammad Kamgar
11 papers
BS
Bruce Spinowitz
10 papers
Michael Rocco
10 papers
SF
Steven Fishbane
10 papers
Stuart Sprague
9 papers
Suzanne Oparil
8 papers
EL
Edgar Lerma
7 papers
Nicolas Guzman
7 papers
Glenn Chertow
6 papers

Clinical trials

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
Site PI · Recruiting · Phase 3
Biogen
2025–2031
A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease
Site PI · Recruiting · Phase 1, Phase 2
GC Biopharma Corp
2025–2028
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Site PI · Recruiting · Phase 3
Biogen
2025–2029